Discover the Future of Health

EmeraMed: Targeting the cause of diseases.

Oxidative stress releases free radicals and is a major part of all illnesses. Irminix® captures free radicals, which are unstable molecules that can damage the cells in your body. Additionally Irminix® captures the heavy metals mercury and iron which helps create free radicals and thereby helps restore normal function to the mitochondria and overall health.

COPD: A Phase 2a clinical trial has been completed in summer of 2018 and found Irminix® to be safe with no adverse effects.

Mercury poisoning: Orphan Drug Designation has been granted for the prevention and treatment of mercury toxicity in the EU and USA. Phase 1 and Phase 2a clinical studies have been performed and found Irminix® to be effective and safe with no adverse effects.

Other conditions: Preclinical studies are ongoing for several other indications.

Latest Information

Irminix® is an exceptionally safe and effective lipophilic, blood-brain-barrier passing metal chelator and antioxidant being developed by EmeraMed Limited. It is currently going through the European Medical Agency (EMA) and the United States Food and Drug Administration (FDA) drug approval process.

Counterfeit Irminix® is being sold under our various trade names (OSR#1®, NBMI, Emeramide) and tests have shown that it is not Irminix®. Irminix® may be available in your country in compliance with various regulations through our Early Access Programme.